Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total

Not Applicable (1)

P 1 (1)

Trial Status

Completed3

Not Yet Recruiting1

Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (5)

Showing 5 of 5 trials

NCT07554664Not Yet Recruiting

Central Sensitization, Work-Related Stress, and Musculoskeletal Symptoms in Desk-Based Workers With and Without Migraine

NCT06727825Completed

Evaluation of Grass Pollen Sensitization Among Professionals Exposed or Not Exposed to Flour

NCT06930378Not ApplicableRecruiting

Improvement in Breast Skin Sensibility After Breast Reconstruction: a Comparison of 3 Surgical Techniques

NCT03397862Phase 1Completed

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

NCT01842711Completed

Cumulative Irritation Patch Test

Showing all 5 trials

Sensitization